share_log

Wells Fargo Maintains Equal-Weight on Regulus Therapeutics, Raises Price Target to $3

Wells Fargo Maintains Equal-Weight on Regulus Therapeutics, Raises Price Target to $3

富国银行维持Regulus Therapeutics的同等权重,将目标股价上调至3美元
Benzinga ·  03/13 06:53

Wells Fargo analyst Jim Birchenough maintains Regulus Therapeutics (NASDAQ:RGLS) with a Equal-Weight and raises the price target from $2 to $3.

富国银行分析师吉姆·伯奇诺维持 Regulus Therapeutics(纳斯达克股票代码:RGLS)的权重相同,并将目标股价从2美元上调至3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发